China Starts to Pay for Pharmaceutical Services.
Haishaerjiang Wushouer,Luwen Shi,Xiaodong Guan,Yimin Cui
DOI: https://doi.org/10.1111/jcpt.13721
2022-01-01
Journal of Clinical Pharmacy and Therapeutics
Abstract:On 8 April 2022, the Healthcare Security Bureau of Fujian province of China released a policy regarding the payment of pharmaceutical services. This is another exploration of paying for pharmaceutical services after Chongqing's pilot implementation in 2013. The city of Chongqing once set up a pharmaceutical service fee as a complementary policy to compensate the operational cost of public hospitals after the zero-mark-up policy. However, the policy was terminated in 2017. Different from many other countries, China's hospitals operate their own pharmacies. Generally, pharmaceutical services in China refers to the drug supply related services that the hospitals or the retail pharmacies provided (including drug procurement, storage, management, dispensing, etc.), and the clinical pharmacy services (prescription audit, medication consultation, education, intravenous admixture services, pharmaceutical care, etc.). Since 1954, China implemented the drug mark-up policy which allowed medical institutions to sell drugs at a rate that did not exceed 15% of the drug's actual per-unit purchase price. This policy aimed to remedy insufficient compensation in public hospitals and maintain their survival and development. However, the drug mark-up policy led to profit-seeking behaviour in hospitals which brought a series of problems, including an increasing medication burden for patients and inappropriate prescribing. In 2009, China launched the zero-mark-up policy as part of the new round of medical reform. The policy stated that local governments can set up pharmaceutical service fees to compensate for the cost after implementing the zero-mark-up policy. This offered an opportunity for the pharmacy service to transfer from medicationcentred to patient-centred. Studies showed that pharmacist-led pharmaceutical services could significantly improve patient outcome, level of rational drug use, and efficiency of medical resources utilization. As an integral part of the medical team, it is self-evident that the important role of pharmacists in clinical treatment activities. Same as the training of physicians, the training of pharmacists is inseparable from high-quality clinical practice. Like any medical service activity, the development of pharmaceutical services costs. Reasonable compensation for the costs of pharmaceutical services is the basis for training high-quality pharmacists, and is also the guarantee for providing high value pharmaceutical care. In February 2020, the National Healthcare Security Administration and the National Health Commission of China jointly issued a policy that clearly stated that the value of pharmaceutical services should be reasonably covered, that is, “...the cost and value of pharmaceutical services should be considered in the price of medical services to support the development of pharmaceutical services. Encourage pharmacists to play an active role in promoting rational drug use and reducing waste of resources.” The exploration in Fujian province provides a good template for China to further develop high-quality pharmaceutical services. In the future, decision-making departments should consider the cost and value of pharmaceutical services as a whole, promote the transformation of pharmaceutical service models, strengthen the cultivation of pharmacists, and safeguard patients' health by reasonably compensating for pharmaceutical service costs.